Infections after bone marrow transplantation using cyclosporine

Area of Science:

• Hematology
• Immunology
• Infectious Diseases

Background:

• Bone marrow transplantation (BMT) is a critical treatment for myeloid leukemias.
• Immunosuppression is essential post-BMT to prevent graft rejection and graft-versus-host disease (GVHD).
• Cyclosporine is a primary immunosuppressant used in BMT protocols.

Purpose of the Study:

• To evaluate the incidence and types of infections in patients undergoing BMT for myeloid leukemia.
• To assess the role of cyclosporine as the main immunosuppressant in infection rates.
• To analyze the relationship between infection, GVHD, and neurological complications.

Main Methods:

• Retrospective analysis of 86 consecutive patients undergoing BMT for acute or chronic myeloid leukemia.
• Patients received cyclosporine as the primary immunosuppressive agent.
• Infection surveillance and management protocols were followed, including prophylactic antifungals.

Main Results:

• Overall infection incidence was low in patients treated with cyclosporine.
• Severe bacterial infections were infrequent, primarily caused by Gram-positive cocci.
• Early bacterial infections correlated with severe graft-versus-host disease.
• Prophylactic nystatin and amphotericin effectively prevented fungal infections.
• Viral infections were not more common than in other series; however, mismatched grafts were associated with neurological complications resembling encephalitis.

Conclusions:

• Cyclosporine-based immunosuppression in BMT for myeloid leukemia is associated with a low incidence of infection.
• Prophylactic antifungal therapy is effective in preventing fungal complications.
• Early bacterial infections and neurological complications in mismatched grafts require careful monitoring and management.